');
} else {
var query = elem.find('.keywords').html();
$.ajax({
context: elem,
url: 'https://wn.com/api/upge/cheetah-search-adv/video',
cache: true,
data: {
'query': query
},
dataType: 'jsonp',
success: function(text) {
if (text.length > 0) {
video_id = text[0].id;
elem.find('.player').html('
');
}
}
});
}
}
var stopAllYouTubeVideos = function() {
var iframes = document.querySelectorAll('iframe');
Array.prototype.forEach.call(iframes, function(iframe) {
iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*');
});
}
jQuery(function() {
jQuery(".playVideo").live("click", function() {
if(!$(this).hasClass("played")){
stopAllYouTubeVideos();
var elem = $(this);
setTimeout(function(){
mouseOverMe(elem);
}, 1000);
}
});
jQuery(".description_box .expandContent").live("click", function() {
elem = $(this).parent().parent().parent().find('.descContent');
if(elem.height() > 51) {
elem.css('height', '44px');
$(this).html('Show More
');
}else{
elem.css('height', 'auto');
$(this).html('Hide
');
}
});
jQuery('.interview-play-off').click(function() {
$(".interview-play-off").hide();
$(".interview-play").show();
$(".videoplayer-control-pause").click();
});
jQuery(".video-desc .show_author_videos").live("click", function() {
query = $(this).attr('title');
container = $(this).parent().parent().parent().find('.video-author-thumbs');
$(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px');
jQuery.ajax({
url: '/api/upge/cheetah-photo-search/videoresults',
data: {'query': query},
success: function(text) {
if(!text) { text = i18n("No results"); }
container.html(jQuery(text));
}
});
});
});
// -->
Latest News for: dll3
Edit
PR Newswire
30 Mar 2026
FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor) ... DLL3 has been reported to be upregulated in multiple solid tumor types, including in SCLC, NETs, NSCLC, melanoma, among others.
Edit
Nasdaq Globe Newswire
02 Feb 2026
MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics ...
Edit
Public Technologies
02 Feb 2026
"I am highly encouraged by the data generated in my group suggesting a favorable distribution profile of MP0712, a DLL3-targeted radiopharmaceutical for patients with SCLC and NEC cancers," said Dr.